
OptiMedica
Founded Year
2004Stage
Acquired | AcquiredTotal Raised
$92.96MValuation
$0000About OptiMedica
OptiMedica is a global ophthalmic device company dedicated to developing performance-driven technologies that improve patient outcomes. Exclusively focused in the cataract therapeutic area, the company has developed the Catalys Precision Laser System to transform existing standards of care in cataract surgery. The company has also developed and commercialized the PASCAL Method of retinal photocoagulation, which was acquired by Topcon Corp. in August 2010. In August 2013, OptiMedica was acquired by Abbott Laboratories. The valuation of OptiMedica was $250 million. Other terms of the deal were not released.
OptiMedica Patents
OptiMedica has filed 178 patents.
The 3 most popular patent topics include:
- Ophthalmology
- Eye surgery
- Vision

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
7/27/2018 | 5/23/2023 | Eye surgery, Ophthalmology, Vision, Diseases of the eye and adnexa, Medical equipment | Grant |
Application Date | 7/27/2018 |
---|---|
Grant Date | 5/23/2023 |
Title | |
Related Topics | Eye surgery, Ophthalmology, Vision, Diseases of the eye and adnexa, Medical equipment |
Status | Grant |
Latest OptiMedica News
Feb 10, 2023
2023" - https://www.reportlinker.com/p06277184/?utm_source=GNW , NIDEK Co. Ltd., STAAR Surgical Company, and Johnson & Johnson. The global cataract surgery devices and equipment market will grow from $6.61 billion in 2022 to $7.11 billion in 2023 at a compound annual growth rate (CAGR) of 7.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The cataract surgery devices and equipment market is expected to grow to $9.18 billion in 2027 at a CAGR of 6.6%. The cataract surgery devices and equipment market consist of sales of ophthalmic viscoelastic devices, phacoemulsification equipment, and femtosecond laser equipment that are used for the cataract surgery.Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. Cataract surgery devices includes instruments that are used for performing cataract surgery in the treatment of cataracts, a condition in which the lens of the eye becomes progressively opaque, resulting in blurred vision. North America was the largest region in the cataract surgery devices and equipment market in 2022.Asia Pacific was the second-largest region in cataract surgery devices and equipment market. The regions covered in the cataract surgery devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The main types of cataract surgery devices and equipment are intraocular lens (IOL), ophthalmic viscoelastic device (OVD), phacoemulsification equipment, and femtosecond laser equipment.An ophthalmic viscoelastic device (OVD) is used for performing cataract surgeries. The cataract surgery devices and equipment are used for various surgery types such as extracapsular cataract extraction, phacoemulsification, femtosecond laser, and others. These are used by end-users such as ophthalmology centres, hospitals, and clinics. The major growth driver for this industry has been the global aging population.In 2020, there were 1 billion persons aged 65 years or over in the global population. This number is projected to double to 1.5 billion in 2050. The cases of cataracts in the geriatric population are also expected to increase in the same proportion. According to World Health Organization, the number of cataract cases is expected to increase by 78% by 2050 in the U.S. alone. This presents a huge market for cataract surgery equipment manufacturers shortly by expanding the customer base due to the fast-growing geriatric population. For instance, the population of China is getting older faster than anywhere else in the world, this presents a huge market for the cataract surgery device manufacturers in China. The major challenge that is faced by this industry is the low level of awareness about eye disorders, especially cataracts.Many people do not have proper knowledge about the symptoms of cataracts and do not get the treatment done. This leads to potential revenue loss for the cataract surgery device manufacturers because of the low number of end-users. For example, as per a study done by NCBI, out of 1552 respondents, 89.9% had heard of cataracts but only 42% were aware of any symptom of cataracts, low awareness of cataract symptoms acts as a major restraint for the cataract surgery equipment industry. The cataract surgery devices and equipment industry has witnessed many positive changes introduced by the market players, the most prominent one being the introduction of laser technology.Laser-assisted cataract surgery is used to gather information about the lens, to make the corneal incision, and for the opening in the lens capsule. The advent of laser technology has caused a significant impact on this industry by bringing in new levels of safety and accuracy and advancing cataract surgery.Femtosecond laser platforms have significantly contributed to the precision of cataract surgeries being performed and may soon surpass the traditional hand-held surgeries. For example, Abbott laboratories which lacked this technology, acquired Optimedica for $250 million to enter the laser cataract surgery devices market after witnessing the huge demand and benefits of laser technology. The ophthalmology and medical equipment industry are subject to numerous stringent regulations and the cataract surgery device equipment manufacturers are no exception. These manufacturers need to comply with several regulations of which the European Medical Device Directives and the U.S. Health Care Compliance is the most prominent one. The European Medical Device Directive requires a manufacturer to meet the harmonized standards for placing their devices in the European market. Similarly the U.S. Health Care Compliance has laid down certain guidelines related to standards of business conduct to be followed by the Pharmaceutical manufacturers. The Medicines and Healthcare products Regulatory Agency (MHRA), which regulates the safety of medical devices in the UK, has issued an urgent notice to Carl Zeiss Meditec, for voluntarily recalling a small batch of its intraocular lenses (IOL). The recall was initiated after the manufacturer detected mislabelling of its IOL, Aaren Scientific EC-3 hydrophobic lens with the wrong dioptric power. Therefore, the manufacturers need to comply strictly with the correct labeling of dioptric power on the IOLs. In October 2020, Katena Products, a US-based manufacturer of ophthalmic surgical instruments, acquired Micro-select instruments for an undisclosed amount.The acquisition would help Katena’s growth in instrument manufacturing vertical. Micro-select instruments is a US-based manufacturer of ophthalmic surgery instruments. The countries covered in the cataract surgery devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The cataract surgery devices and equipment market research report is one of a series of new reports that provides cataract surgery devices and equipment market statistics, including cataract surgery devices and equipment industry global market size, regional shares, competitors with a cataract surgery devices and equipment market share, detailed cataract surgery devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cataract surgery devices and equipment industry. This cataract surgery devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
OptiMedica Frequently Asked Questions (FAQ)
When was OptiMedica founded?
OptiMedica was founded in 2004.
Where is OptiMedica's headquarters?
OptiMedica's headquarters is located at 1310 Moffett Park Drive, Sunnyvale.
What is OptiMedica's latest funding round?
OptiMedica's latest funding round is Acquired.
How much did OptiMedica raise?
OptiMedica raised a total of $92.96M.
Who are the investors of OptiMedica?
Investors of OptiMedica include Abbott, Alloy Ventures, Kleiner Perkins Caufield & Byers, DAG Ventures, EDBI and 8 more.
Who are OptiMedica's competitors?
Competitors of OptiMedica include Cornerstone Pharmaceuticals, Esperance Pharmaceuticals, Aegerion Pharmaceuticals, Ikaria, Presidio Pharmaceuticals and 12 more.
Compare OptiMedica to Competitors
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
Urigen specializes in the design and commercialization of innovative products for patients with urological ailments. The company develops products for amelioration of Painful Bladder Syndrome (PBS), Urethritis, Nocturia and Over Active Bladder (OAB).
Drais Pharmaceuticals, Inc. is dedicated to the development of therapeutic treatments that address unmet medical needs and provide significant benefits over currently available therapies.
Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.
Through a series of acquisitions, Albea Pharmaceuticals intends to build a rapidly growing, profitable, and pan-European pharmaceutical company with a portfolio of marketed products, a direct sales and marketing organization in the major European countries (UK, Germany, France, Italy and Spain), and a pipeline of products in various stages of clinical development.'
Presidio Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics. Presidio's focus is on effective therapies for hepatitis C virus (HCV) infection. With a pipeline consisting of compounds targeting both the NS5A and NS5B proteins of HCV, Presidio is positioned to compete in the growing HCV therapy market. Presidio's goal is to discover and advance small-molecule, antiviral drug candidates that are potent, have pan-genotypic antiviral activity, offer convenient once-daily oral dosing and can be combined with other classes of HCV antivirals to combat viral resistance. The best future combination regimens will require such characteristics, to simplify patient treatment and to ensure that drug therapy will be effective against the wide variety of known HCV genotypes.